Two hundred sixty-seven patients with advanced epithelial ovarian carcinoma were randomized to cis-platinum and cyclophosphamide versus cis-platinum, cyclophosphamide, and doxorubicin. Complete pathological response, evaluated at second-look laparotomy and survival, showed no differences between the two treatment groups. Recurrence-free survival after negative second look was 61% at 24 months.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0090-8258(87)90210-1 | DOI Listing |
Publication Analysis
Top Keywords
ovarian carcinoma
8
cis-platinum cyclophosphamide
8
randomized study
4
study cyclophosphamide
4
cyclophosphamide cis-platinum
4
cis-platinum doxorubicin
4
doxorubicin advanced
4
advanced ovarian
4
carcinoma sixty-seven
4
sixty-seven patients
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!